Generic Effective Rate (GER) Explained

Generic Effective Rate is a PBM-set target reimbursement rate for generic prescriptions, calculated across your entire quarterly dispensing volume. If your average generic reimbursement falls below the GER target, the PBM claws back the difference at reconciliation.

Think of it as a "generic dispensing performance bonus" — except the bonus is set at a level most independents can't hit, and the "reward" is not being clawed back rather than being paid more.

GER targets are set by PBM and refreshed quarterly. Caremark, Express Scripts, and OptumRx all use GER but with different target levels and calculation methodologies.

1. Patient mix matters. Older patients on complex chronic regimens (5+ medications, multiple therapeutic classes) tend to have lower generic percentage than younger patients on simpler regimens. Independents with older demographics face structural GER headwinds.

2. Specialty niches lower generic mix. Compounding pharmacies, HRT-focused pharmacies, and specialty independents typically dispense fewer generics (compounded formulations aren't "generic" in the PBM sense). GER targets don't adjust for specialty focus.

3. Independent generic pricing is often below MAC. Even when dispensing appropriately, independents pay higher wholesale acquisition costs than chains and get reimbursed at MAC (Maximum Allowable Cost) — which creates the GER shortfall on the PBM books.

4. Chain pharmacies have GER advantages. Chains negotiate lower MAC in exchange for higher volume commitments. This means chain generic reimbursements clear GER targets by design, while independents struggle to hit the same targets on unfavourable MAC schedules.

All three major PBMs have formal GER dispute processes. Most independents don't use them.

Success rate on properly documented GER disputes: ~40% for Express Scripts, ~35% for CVS Caremark, ~30% for OptumRx. Recovery rarely covers the full clawback but frequently reduces it by 40-70%.

Documentation requirements: (1) therapeutic-class breakdown of your generic dispensing rate, (2) clinical rationale for below-target generic mix (patient demographic, specialty focus, medically-necessary brand dispensing), (3) MAC-vs-WAC evidence for below-cost generic reimbursements.

Independents in PSAOs (AmerisourceBergen Elevate, Cardinal LEADER, McKesson Health Mart Atlas) get GER dispute support from their PSAO — recovery rate is higher than solo dispute filing.